

**AWARD NUMBER:**

W81XWH-15-1-0072

**TITLE:**

Development of Tethered Hsp90 Inhibitors Carrying  
Radioiodinated Probes to Specifically Discriminate and Kill  
Malignant Breast Tumor Cells

**PRINCIPAL INVESTIGATOR:**

Timothy Haystead

**CONTRACTING ORGANIZATION:**

Duke University  
Durham, NC 27708

**REPORT DATE:**

May 2016

**TYPE OF REPORT:**

Annual

**PREPARED FOR:** U.S. Army Medical Research and Materiel Command  
Fort Detrick, Maryland 21702-5012

**DISTRIBUTION STATEMENT:** Approved for Public Release;  
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

<b>REPORT DOCUMENTATION PAGE</b>			<i>Form Approved</i> <i>OMB No. 0704-0188</i>		
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. <b>PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.</b>					
<b>1. REPORT DATE</b> May 2016		<b>2. REPORT TYPE</b> Annual		<b>3. DATES COVERED</b> 1 May 2015 - 30 Apr 2016	
<b>4. TITLE AND SUBTITLE</b>  Development of Tethered Hsp90 Inhibitors Carrying Radioiodinated Probes to Specifically Discriminate and Kill Malignant Breast Tumor Cells			<b>5a. CONTRACT NUMBER</b>		
			<b>5b. GRANT NUMBER</b> W81XWH-15-1-0072		
			<b>5c. PROGRAM ELEMENT NUMBER</b>		
<b>6. AUTHOR(S)</b> Timothy Haystead Mike Zalutsky  E-Mail:timothy.haystead@dm.duke.edu			<b>5d. PROJECT NUMBER</b>		
			<b>5e. TASK NUMBER</b>		
			<b>5f. WORK UNIT NUMBER</b>		
<b>7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)</b> Duke University, office of sponsored research, 2200 W. Main Street, Suite 710 Box 104010, Durham NC 27705			<b>8. PERFORMING ORGANIZATION REPORT NUMBER</b>		
<b>9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)</b>  U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012			<b>10. SPONSOR/MONITOR'S ACRONYM(S)</b>		
			<b>11. SPONSOR/MONITOR'S REPORT NUMBER(S)</b>		
<b>12. DISTRIBUTION / AVAILABILITY STATEMENT</b>  Approved for Public Release; Distribution Unlimited					
<b>13. SUPPLEMENTARY NOTES</b>					
<b>14. ABSTRACT</b> We have proposed to develop tethered Hsp90 inhibitor capable of carrying various radioactive iodine isotopes for early detection and ablation of metastatic breast cancers. These probes specifically target a surface form of heat shock protein 90 (eHsp90)that is expressed on malignant cells and internalized. In this report we describe our chemistry efforts to synthesize a non-radioactive tethered Hsp90 inhibitor, methods developed for stannylation of the molecule such that it can be effectively radioiodinated with either I121 or I124. Two paths of synthesis were developed. A standard operating procedure was developed and transferred to our collaborator who developed protocols for radioiodination. An in active control molecule was also developed. These molecules will be tested as imaging agents in mouse models of breast cancer.					
<b>15. SUBJECT TERMS</b> Radiodination, tethered Hsp90 inhibitor, malignant breast tumor, ectopic Hsp90					
<b>16. SECURITY CLASSIFICATION OF:</b>			<b>17. LIMITATION OF ABSTRACT</b>	<b>18. NUMBER OF PAGES</b>	<b>19a. NAME OF RESPONSIBLE PERSON</b> USAMRMC
<b>a. REPORT</b>	<b>b. ABSTRACT</b>	<b>c. THIS PAGE</b>			<b>19b. TELEPHONE NUMBER (include area code)</b>
Unclassified	Unclassified	Unclassified	Unclassified	16	

## Table of Contents

	<u>Page</u>
<b>1. Introduction.....</b>	<b>2</b>
<b>2. Keywords.....</b>	<b>2</b>
<b>3. Accomplishments.....</b>	<b>3</b>
<b>4. Impact.....</b>	<b>5</b>
<b>5. Changes/Problems.....</b>	<b>5</b>
<b>6. Products.....</b>	<b>5</b>
<b>7. Participants &amp; Other Collaborating Organizations.....</b>	<b>5</b>
<b>8. Special Reporting Requirements.....</b>	<b>5</b>
<b>9. Appendices.....</b>	<b>5</b>

## 1. Introduction


In the US, routine breast cancer screening results in over 1.6 million biopsies annually leading to the diagnosis and surgical resection of breast cancer or breast carcinoma *in situ* in over 250,000 women respectively. Unfortunately, the sensitivity but low specificity of screening has led to concerns about over treatment of indolent disease, as evidenced by the increased incidence and treatment of early stage breast cancer without a concomitant decrease in the nearly 40,000 breast cancer deaths annually. Clinical data indicate a strong link between high expression/activation of Heat shock protein 90 (Hsp90) with poor prognosis in malignant breast cancer (1, 2). Specifically, immunohistochemical analysis of breast cancer cell lines and 655 primary breast cancers (including 331 ER+ and 324 ER- tumors) showed increased Hsp90 expression in all breast cancer cell lines, and in nearly 90% of primary breast cancers (2). A recent study at our institution evaluated Hsp90 gene expression from profiles of over 4,000 breast cancer patients from 23 publically available gene expression databases, which also reported overall survival data from over 1000 patients. This study confirmed up regulated Hsp90 was associated with poor overall survival in all breast cancer subtypes including estrogen (ER) negative, HER2 negative and triple negative breast cancers (1). Our laboratories recently developed a series of optical and iodinated tethered Hsp90 inhibitors that have exquisite selectivity *in vivo* for metastatic breast tumors expressing ectopic (cell surface) Hsp90 (3). We also discovered that ectopically expressed Hsp90 is rapidly internalized and can carry these tethered inhibitors specifically into the breast cancer cells. This work in tandem with published clinical results suggests that selective targeting of Hsp90 up regulated in malignancy may present an opportunity to not only discriminate indolent tumors from metastatic disease, but also offer a molecularly targeted radiotherapy approach for body wide tumor ablation with low normal tissue toxicity. Herein, we propose to develop a series of tethered Hsp90 inhibitors capable of selectively delivering radioiodine ( $^{124}\text{I}$  and  $^{131}\text{I}$ ) or  $^{211}\text{At}$  to malignant tumor cells. We envisage a process in which a patient, after standard of care breast exam, is first evaluated for malignancy vs. indolent disease by positron emission tomography (PET) imaging using  $^{124}\text{I}$ -labeled tethered inhibitors. Then, in patients with malignancies detected in high contrast to normal tissues, targeted radiotherapy would be preformed at patient-optimized doses of inhibitor labeled with the  $\beta$ -emitter  $^{131}\text{I}$  or the  $\alpha$ -emitter  $^{211}\text{At}$ . **This is an attractive strategy for breast cancer because the same molecules can be used to not only discriminate indolent disease from metastatic, but also enables selective tumor ablation on a personalized level, potentially mitigating life altering side effects commonly associated with current chemotherapeutics or radiation strategies.**

## 2. Keywords

Radioiodinated, Tethered Hsp90 inhibitor, malignant breast cancer, stannylation.

### 3. Accomplishments.

As mentioned above, we previously reported both fluorescein and iodinated probes (*1*). To get the cellular selectivity of our fluorescein probe along with the capabilities of carrying a putative, PET/SPECT imaging agent or radio toxic agent, we need a probe with both imaging moieties. Such a synthesis requires compound that can be easily be converted to the desired radio-labeled iodine compound at a later stage. The approach, as shown in Scheme 1, allows for introduction of a variety of iodine isotopes, via tin-iodine exchange, at two alternative steps in the procedure. Thus (path **A**), compound **1** is converted, via reductive amination to the aryl iodide **2**. Compound **2** is converted by palladium mediated halogen-tin exchange(2) to the tin derivative **3**. This compound is further treated with FITC (fluorescein isothiocyanate) to give the precursor **4**, which can be converted with hot iodine(3) to the desired product **5**. Conversely (path **B**), compound **3** can be converted back to labeled **2**, which can then be reacted with FITC to give the final product **5**. Both routes have been explored successfully with cold iodine. The iodination step from the tin precursor was much cleaner when the tin was sequestered in the reaction. Reaction paths **A** and **B** have been successfully explored with  $^{124}\text{I}$ . It is also possible to convert compound **5** to compound **4** using the palladium mediated halogen-tin exchange reaction.



Scheme 1. Two paths to the synthesis a probe incorporating both fluorescein and hot iodine for both active (**5**) and inactive (**12**) probes.

To obtain a control compound with very similar physical properties but lacking the ability to bind to Hsp90, we also made a dimethyl amide analog **12**. The addition of the methyl groups blocks an important hydrogen bond between the Hsp90 ligand and an aspartic acid on Hsp90 in the active site. Control analog **12** was made in an analogous fashion to compound **5**, as shown in Scheme 1. The control chemistry has not been explored with  $^{124}\text{I}$ . Compounds **5** and **12** are referred to internally as **HS-113** and **HS-212**, respectively. Experimental details are included in the appendix.

- (1) Barrott, J. J., Hughes, P. F., Osada, T., Yang, X. Y., Hartman, Z. C., Loisel, D. R., Spector, N. L., Neckers, L., Rajaram, N., Hu, F. Y., Ramanujam, N., Vaidyanathan, G., Zalutsky, M. R., Lyerly, H. K., and Haystead, T. A. (2013) Optical and Radioiodinated Tethered Hsp90 Inhibitors Reveal Selective Internalization of Ectopic Hsp90 in Malignant Breast Tumor Cells. *Chemistry & Biology* 20, 1187-1197.
- (2) Chun, J.-H., and Pike, V. W. (2012) Regiospecific Syntheses of Functionalized Diaryliodonium Tosylates via Hydroxy(tosyloxy)iodo arenes Generated in Situ from (Diacetoxyiodo)arenes. *Journal of Organic Chemistry* 77, 1931-1938.
- (3) Kozirowski, J., Henssen, C., and Weinreich, R. (1998) A new convenient route to radioiodinated N-succinimidyl 3- and 4-iodobenzoate, two reagents for radioiodination of proteins. *Applied Radiation and Isotopes* 49, 955-959.

**4. Impact.** The successful synthesis of both active and inactive tethered Hsp90 carrying iodine that can be successfully radioiodinated is an important milestone. Two methods of synthesis were developed that will greatly facilitate translation of this technology to clinical practice. The Zalutsky laboratory have also developed methodologies that enable the radioiodination of both I121 and I 124 versions reproducibly. Work is currently ongoing to radio-iodinate the inactive control molecule. This latter molecule will validate that our probes are specifically targeting tumors by binding surface Hsp90. Next steps will involve testing these newly synthesized molecules in mouse models of breast cancer. Success in these experiments will enable us to advance the project to testing the effects of delivery lethal forms of iodine such I131 or the alpha emitter At211.

#### **5. Changes/Problems.**

None to report

#### **6. Products**

Two novel radio-iodinated tethered Hsp90 inhibitors have been developed shown in Scheme 1.

#### **7. Participants & Other Collaborating Organizations.....**

<b>Grants.gov ID Number</b>	GRANT11490422
<b>Principal Investigator</b>	Michael Zalutsky
<b>Performing Organization</b>	Duke University
<b>Contracting Organization</b>	Duke University
<b>Partner Budget Requested</b>	
<b>Direct Costs</b>	
<b>Indirect Costs</b>	


#### **8. Special Reporting Requirements**

none


#### **9. Appendices**

##### **Synthetic experimental details**


Reagents were obtained from commercial sources and used without further purification. Proton NMR spectra were obtained on Varian 400 and 500 MHz spectrometers. LC/MS were obtained on an Agilent ion-trap LC/MS system. HRMS results were obtained on an Agilent 6224 LCMS-TOF and are reported as an average of four runs. Compound **1** was previously reported(*1*).




Synthetic scheme for compounds described below.




Amine **1** (260 mg, 431  $\mu\text{mol}$ ) and 3-iodobenzaldehyde (105 mg, 452  $\mu\text{mol}$ ) were dissolved in dichloroethane (4 mL) and treated with sodium triacetoxyborohydride (137 mg, 646  $\mu\text{mol}$ ) and stirred at RT for 3 days. The reaction mixture was then concentrated and chromatographed (silica gel, 0 to 20% 9/1 : MeOH/NH<sub>3</sub> in CH<sub>2</sub>Cl<sub>2</sub>) to give iodide **2** (203 mg, 57%) as a clear oil. LC/MS gives  $m/z = 820.4 [M+1]^+$ . Bisalkylation product was also isolated (91 mg, 21%) as an oil. LC/MS gives  $m/z = 1036.3 [M+1]^+$ . <sup>1</sup>H-NMR (DMSO-*d*<sub>6</sub>)  $\delta$  8.41 (t, *J* = 5 Hz, 1H), 7.92 (br s, 1H), 7.74 (d, *J* = 8 Hz, 1H), 7.76 (br s, 1H), 7.56 (d, *J* = 8 Hz, 1H), 7.32 (d, *J* = 8 Hz, 1H), 7.26 (br s, 1H), 7.10 (t, *J* = 8 Hz, 1H), 6.77 (d, *J* = 2 Hz, 1H), 6.67 (dd, *J* = 2, 8 Hz, 1H), 3.63 (s, 2H), 3.38-3.52 (m, 20H), 3.20 (q, *J* = 6 Hz, 2H), 2.92 (s, 2H), 2.40 (s, 3H), 2.32 (s, 2H), 1.80 (p, *J* = 6 Hz, 2H), 1.62, (p, *J* = 6 Hz, 2H), 1.01 (s, 6H).




Aryliodide **2** (230 mg, 280  $\mu\text{mol}$ ), hexamethylditin (101 mg, 308  $\mu\text{mol}$ ) and tetrakis triphenylphosphine palladium(0) (6.48 mg 5.61  $\mu\text{mol}$ ) were slurried in dioxane (5 mL), purged with nitrogen and heated to 100  $^{\circ}\text{C}$  for 45 m. The reaction mixture was then concentrated and chromatographed (silica gel, 0 to 10% 9/1 : MeOH/ $\text{NH}_3$  in  $\text{CH}_2\text{Cl}_2$ ) to give the tin compound **3** (213 mg, 89%) as a glass containing dark material (Pd?). The sample was further purified by prep HPLC (Agilent Prep C-18, 2.5 x 25 cm, 30 to 100 % MeOH w/2% formic acid, 20 mL/min) and concentrated to give the tin product **3** (78 mg) as a clear oil. LC/MS gave a single peak with  $m/z = 858.4$   $[\text{M}+1]^+$ .  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  8.35 (s, 1H, formate), 7.99 (br s, 1H), 7.53 (d,  $J = 8.4$  Hz, 1H), 7.49 (br s, 1H), 7.43 (dm,  $J = 7$  Hz, 1H), 7.34 (dm,  $J = 7$  Hz, 1H), 7.29 (dd,  $J = 7$  Hz, 1H), 6.74 (d,  $J = 2$  Hz, 1H), 6.55 (dd,  $J = 2, 8.4$  Hz, 1H), 6.44 (v br s, 1H), 4.06 (s, 2H), 3.49-3.59 (m, 16H), 3.47 (m, 4H), 3.24 (t,  $J = 6.2$  Hz, 2H) 3.06 (t,  $J = 6.2$  Hz, 2H), 2.77 (s, 2H), 2.48 (s, 3H), 2.34 (s, 2H), 1.93 (p,  $J = 6.2$  Hz, 2H), 1.88 (p,  $J = 6.2$  Hz, 2H), 1.05 (s, 6H), 0.23 (s et al, 9H);  $^{13}\text{C}$  NMR ( $\text{CDCl}_3$ )  $\delta$  193.7, 171.79, 167.09 (formate), 151.14, 149.98, 149.31, 143.81, 142.68, 137.35, 136.77, 131.11, 130.01, 129.69, 128.65, 117.26, 112.86, 109.06, 106.33, 70.67, 70.63, 70.55, 70.51, 70.47, 70.38, 70, 69.64, 69.08, 52.52, 50.92, 45.88, 41.01, 40.34, 37.66, 35.97, 29.13, 28.54, 25.45, 13.56, -9.36.




Aryltin compound **3** (116 mg, 135  $\mu\text{mol}$ ) was dissolved in DMSO (200  $\mu\text{L}$ ) and treated with FITC (53 mg, 135  $\mu\text{mol}$ ) dissolved in DMSO (200  $\mu\text{L}$ ) followed by Hunig's base (around 35 mg, 270  $\mu\text{mol}$ ). The mixture was purified by prep HPLC (30 to 100% methanol, 20 mL/m, Agilent C-18, 21.1 x 25 cm) to give product **4** (68 mg, 40%) as a yellow solid. LC/MS gave  $m/z = 1247.4$   $[\text{M}+1]^+$ .  $^1\text{H}$ -NMR ( $\text{DMSO}-d_6$ )  $\delta$  10.17 (br s, 2H), 9.46 (br s, 1H), 8.40 (br t, 1H), 7.94 (s, 1H), 7.92 (br s, 1H), 7.74 (2d, 2H), 7.42 (s, 1H), 7.39 (d, 1H), 7.33 (t, 1H), 7.25 (br s, 1H), 7.23 (d, 1H), 7.18 (d, 1H), 6.76 (s, 1H), 6.67 (br m, 3H), 6.57 (br s, 4H), 5.14 (s, 2H), 3.78 (m, 2H), 3.41-3.51 (m, 20H), 3.20 (m, 2H), 2.91 (s, 2H), 2.39 (s, 3H), 2.32 (s, 2H), 1.89 (m, 2H) 1.80 (m, 2H), 1.00 (s, 6H), 0.25 (s, 9H).




**HS-113.** Aryliodide **2** (31 mg, 38  $\mu\text{mol}$ ) was dissolved in DMSO (200  $\mu\text{L}$ ) and treated with FITC (15 mg, 38  $\mu\text{mol}$ ) dissolved in DMSO (200  $\mu\text{L}$ ) and Hunig's base (10 mg, 76  $\mu\text{mol}$ ). After an hour the compound was chromatographed (silica gel, 0 to 10% 10/1 : MeOH/AcOH in  $\text{CH}_2\text{Cl}_2$ ) to give iodide **5** (28 mg, 62%) as a yellow glass. LC/MS gave  $m/z = 1207.4$   $[\text{M}+1]^+$ .  $^1\text{H-NMR}$  (DMSO- $d_6$ )  $\delta$  10.13 (br s, 2H), 9.47 (br s, 1H), 8.40 (br t, 1H), 7.95 (s, 1H), 7.92 (br s, 1H), 7.77 (d,  $J = 8$  Hz, 1H), 7.73 (d,  $J = 8$  Hz, 1H), 7.69 (s, 1H), 7.64 (d,  $J = 8$  Hz, 1H), 7.33 (d,  $J = 8$  Hz, 1H), 7.25 (br s, 1H), 7.15-1.20 (m, 2H), 6.76 (s, 1H), 6.67 (br m, 3H), 6.57 (br s, 4H), 5.14 (s, 2H), 3.74 (m, 2H), 3.38-3.51 (m, 20H), 3.19 (m, 2H), 2.91 (s, 2H), 2.39 (s, 3H), 2.31 (s, 2H), 1.87 (m, 2H) 1.79 (m, 2H), 1.00 (s, 6H).





**HS-113.** Tin compound **4** (1 mg, 0.8  $\mu\text{mol}$ ) and sodium acetate (3 mg) were dissolved in methanol (1 mL) and treated iodine (8  $\mu\text{L}$  of 0.1 M solution). After about 20 m, an aliquot was removed and analyzed by LC/MS which showed multiple products.



Tin compound **4** (1 mg, 0.8  $\mu\text{mol}$ ) was dissolved in methanol (1 mL) and treated with 1N HCl (3 drops) followed by iodine (8  $\mu\text{L}$  of 0.1 M solution). After about 20 m, an aliquot was removed and analyzed by LC/MS which showed cleaner reaction but with some tin adducts.





Tin compound **4** (1 mg, 0.8  $\mu\text{mol}$ ) was dissolved in methanol (1 mL) and treated with ethylenediamine di-HCl (1 mg in 10  $\mu\text{L}$  of water) followed by iodine (8  $\mu\text{L}$  of 0.1 M solution). The color dissipated instantly. The next day, an aliquot was removed and analyzed by LC/MS which showed the cleanest formation of product **5**.




Amine **1** was dissolved in methylene chloride (50 mL) and treated with di-tert-butyl dicarbonate (940 mg, 1.04 mL, 4.5 mmol). After 30 minutes the reaction mixture was concentrated and chromatographed (silica gel, 0 to 2.5% MeOH in  $\text{CH}_2\text{Cl}_2$ ) to give the product **6** (1.52 g, 50%) as a clear viscous oil. LC/MS gave a single peak with  $m/z = 704.4$ ,  $^1\text{H}$  NMR ( $\text{DMSO-d}_6$ )  $\delta$  8.41 (br t,  $J = 6$  Hz, 1H), 7.92 (br s, 1H), 7.74 (d,  $J = 8$  Hz, 1H), 7.27 (br s, 1H), 6.77 (d,  $J = 2$  Hz, 1H), 6.75 (br t,  $J = 6$  Hz, 1H), 6.68 (dd,  $J = 2, 8$  Hz, 1H), 3.46-5.53 (m, 18H), 3.44 (m, 2H), 3.35 (t,  $J = 6$  Hz, 2H), 3.2 (q,  $J = 6$  Hz, 2H), 2.94 (q,  $J = 6$  Hz, 2H), 2.92 (s, 2H), 2.40 (s, 3H), 2.33 (s, 2H), 1.81 (p,  $J = 6$  Hz, 2H), 1.57 (p,  $J = 6$  Hz, 2H), 1.36 (s, 9H), 1.01 (s, 6H).

Arcs show coupling seen in COSY-NMR.






The dimethyl BOC compound **7** (338 mg, 0.46 mmol) was treated with TFA in  $\text{CH}_2\text{Cl}_2$  for 1 h. This sample was concentrated and purified by prep LC (0 to 100% methanol, 20 mL/m, Agilent C-18, 21.1 x 25 cm) to give **8** (137 mg, 47%) as a clear oil. LC/MS gave a single peak with  $m/z = 632$ .  $4 [M + 1]^+$ .  $^1\text{H-NMR}$  ( $\text{DMSO-d}_6$ )  $\delta$  7.61 (br s, 2H), 7.17 (d,  $J = 8$  Hz, 1H), 6.77 (d,  $J = 2$  Hz, 1H), 6.73 (dd,  $J = 2, 8$  Hz), 5.67 (br s, 1 H), 3.43-3.54 (m 20 H), 3.18 (m, 2H), 2.95 (br s, 6H), 2.90 (s, 2H), 2.85 (m, 2H), 2.40 (s, 3H), 2.33 (s, 2H), 1.72-1.81 (m, 4H), 1.02 (s, 6H).




Amine **8** (133 mg, 210  $\mu\text{mol}$ ) was dissolved in methylene chloride (2 mL) and treated sequentially with 3-iodobenzaldehyde (54 mg, 231  $\mu\text{mol}$ ), acetic acid (24  $\mu\text{L}$ ), and sodium

triaceoxyborohydride (112 mg, 526  $\mu\text{mol}$ ) and stirred at RT. After 1 h, more sodium triaceoxyborohydride (112 mg, 526  $\mu\text{mol}$ ) was added. An hour later the reaction mixture was added to silica, concentrated and chromatographed (silica gel, 0 to 20% 9/1 : MeOH/NH<sub>4</sub>OH in CH<sub>2</sub>Cl<sub>2</sub>) to give the monoalkylated product **9** (69 mg, 38%) as a clear glass. Bis-alkylated product (21 mg) was also isolated as a clear glass. LC/MS gave a peak with  $m/z = 1063.9$  [M+1]<sup>+</sup>. <sup>1</sup>H-NMR (DMSO-d<sub>6</sub>)  $\delta$  7.86 (s, 1H), 7.74 (d, J = 7.5 Hz, 1H), 7.45 (d, J = 7.5 Hz, 1H), 7.21 (t, J = 7.5 Hz, 1H), 7.17 (d, J = 8 Hz, 1H), 6.77 (d, J = 2 Hz, 1H), 6.73 (dd, J = 2, 8 Hz), 5.67 (br s, 1 H), 4.01 (br s, 2H), 3.42-3.54 (m 20 H), 3.17 (m, 2H), 2.95 (br s, 6H), 2.90 (s, 2H), 2.87 (m, 2H), 2.39 (s, 3H), 2.32 (s, 2H), 1.74-1.83 (m, 4H), 1.02 (s, 6H).




Iodide **9** (88 mg, 104  $\mu\text{mol}$ ), hexamethylditin (44 mg, 28  $\mu\text{L}$ , 135  $\mu\text{mol}$ ) and tetrakis triphenylphosphine palladium(0) (2.4 mg, 2.1  $\mu\text{mol}$ ) were slurried in dioxane (2 mL), purged with nitrogen for 30 m and heated to 100 °C for an hour. TLC (9/0.9/0.1 : CH<sub>2</sub>Cl<sub>2</sub>/MeOH/NH<sub>4</sub>OH) showed complete conversion to product. The reaction mixture was concentrated and chromatographed (silica gel, 0 to 25% 9/1 : MeOH/NH<sub>4</sub>OH in CH<sub>2</sub>Cl<sub>2</sub>) to give product tin product **10** (78 mg, 83%) as a glass. LC/MS gives  $m/z = 886.4$  [M+1]<sup>+</sup>. <sup>1</sup>H-NMR (DMSO-d<sub>6</sub>)  $\delta$  8.42 (v br s, 1H), 7.58 (br s, 1H), 7.51 (br m, 1H), 7.39 (br m, 2H), 7.17 (d, J = 8 Hz, 1H), 6.77 (br s, 1H), 6.73 (br d, J = 8 Hz, 1H), 5.67 (t, J = 5 Hz, 1H), 4.10 (br s, 2H), 3.43-3.52 (br m, 20H), 3.17 (q, J = 6 Hz, 2H), 2.97 (m, 2H), 2.97 (br s, 6H), 2.90 (s, 2H), 2.39 (s, 3H), 2.33 (s, 2H), 1.83 (m, 2H), 1.78 (m, 2H), 1.02 (s, 6H), 0.28 (s, 9H).




Tin compound **10** (40 mg, 45  $\mu\text{mol}$ ) was dissolved in ethanol (2 mL) and treated with Hunig's base (2 drops) followed by FITC (21 mg, 54  $\mu\text{mol}$ ). After 30 m, TLC (4/0.9/0.1 : CH<sub>2</sub>Cl<sub>2</sub>/MeOH/NH<sub>4</sub>OH & 9/1 : CH<sub>2</sub>Cl<sub>2</sub>/MeOH) showed no starting amine and a new product. The reaction mixture was concentrated and chromatographed (silica gel, 0 to 20% MeOH in CH<sub>2</sub>Cl<sub>2</sub>) to give tin adduct **11** (33 mg, 57%) as a yellow glass. LC/MS gave a major peak with

$m/z = 1275.5 [M+1]^{+1} . J^{+}$ .  $^1\text{H-NMR}$  (DMSO- $d_6$ )  $\delta$  10.15 (br s, 2H), 9.45 (br s, 1H), 7.94 (s, 1H), 7.74 (d,  $J = 8$  Hz, 1H), 7.43 (s, 1H), 7.38 (m, 1H), 7.33 (m, 2H), 7.24 (d,  $J = 8$  Hz, 1H), 7.17 (t,  $J = 8$  Hz, 1H), 7.16 (d,  $J = 8$  Hz, 1H), 6.76 (s, 1H), 6.72 (d,  $J = 8$  Hz, 1H), 6.67 (br m, 2H), 6.57 (br m, 4H), 5.66 (t,  $J = 5$  Hz, 1H), 5.15 (s, 2H), 3.78 (m, 2H), 3.40-3.51 (m, 20H), 3.17 (q,  $J = 6$  Hz, 2H), 2.94 (br s, 6H), 2.89 (s, 2H), 2.39 (s, 3H), 2.32 (s, 2H), 1.88 (m, 2H), 1.77 (p,  $J = 6$  Hz, 2H), 1.01 (s, 6H), 0.25 (s, 9H).



Iodide **9** (65 mg, 77  $\mu\text{mol}$ ) was dissolved in ethanol (2 mL) and treated with Hunig's base (2 drops) followed by FITC (33 mg, 84  $\mu\text{mol}$ ). After 30 m, TLC (4/0.9/0.1 :  $\text{CH}_2\text{Cl}_2/\text{MeOH}/\text{NH}_4\text{OH}$ ) showed product but a little starting amine remaining so more FITC (12 mg) was added. After 1 h, the reaction mixture was concentrated onto silica gel (2 g) and chromatographed (silica gel, 0 to 20% MeOH in  $\text{CH}_2\text{Cl}_2$ ) to give **12** (84 mg, 88%) as a yellow glass. LC/MS shows a major peak with  $m/z = 1236.9 [M+1]^+$  and  $619.2 [M+2]^{2+}$ .  $^1\text{H-NMR}$  (DMSO- $d_6$ )  $\delta$  7.96 (s, 1H), 7.77 (d,  $J = 7$  Hz, 1H), 7.69 (s, 1H), 7.65 (d,  $J = 7$  Hz, 1H), 7.33 (d,  $J = 7$  Hz, 1H), 7.18 (t,  $J = 7$  Hz, 1H), 7.18 (d,  $J = 8$  Hz, 1H), 7.16 (d,  $J = 7$  Hz, 1H), 6.76 (d,  $J = 2$  Hz, 1H), 6.72 (dd,  $J = 2, 8$  Hz), 6.67 (br s, 2H), 6.57 (br s, 4H), 5.66 (br t,  $J = 5$  Hz, 1H), 5.15 (s, 2H), 3.74 (br m, 2H), 3.41-3.50 (m, 20H), 3.16 (m, 2H), 2.94 (br s, 6H), 2.89 (s, 2H), 2.39 (s, 3H), 2.32 (s, 2H), 1.88 (p,  $J = 6$  Hz, 2H), 1.77 (p,  $J = 6$  Hz, 2H), 1.01 (s, 6H).



Iodide **5** (62 mg, 51  $\mu\text{mol}$ ), hexamethylditin (22 mg, 14  $\mu\text{L}$ , 67  $\mu\text{mol}$ ) and tetrakis triphenylphosphine palladium(0) (2 mg., 1.5  $\mu\text{mol}$ ) were slurried in dioxane (1 mL), purged with nitrogen for 30 m and heated to 100  $^\circ\text{C}$  for an hour. The reaction was concentrated, dissolved in DMSO and chromatographed (50 g Isco C18, 0 to 100% MeOH with 0.2% formic acid in each) to give the tin compound **5** (29 mg., <50%) as an orange solid. This compound was identical to prepared previously using an alternate route (**3** to **4**).

- (1) Hughes, P. F., Barrott, J. J., Carlson, D. A., Loisselle, D. R., Speer, B. L., Bodoor, K., Rund, L. A., and Haystead, T. A. J. (2012) A highly selective Hsp90 affinity chromatography resin with a cleavable linker. *Bioorganic & Medicinal Chemistry* 20, 3298-3305.